0.4000USD-3.16%Mkt Cap: 5.25M USDP/E: —Last update: 2026-05-26
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap5.25M USD
Enterprise Value-16.46M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-19.86M USD
Revenue/Share—
Last Price0.4000 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.26
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.28
EPS (TTM)-3.33
EPS (Forward)-1.55
52W Range
0.26201% of range23.20
52W High23.20 USD
52W Low0.2620 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-229.71%
ROA-124.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.59M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-269.94%
Net Debt-21.96M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.05
Current Ratio3.85
Quick Ratio3.63
Book Value/Sh1.472 USD
Cash/Share1.693 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateMar 9, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)70.00 USD
Target Range30.00 USD – 140.00 USD
# Analysts3
Ownership
Shares Out.13.11M
Float11.44M
Insiders1.90%
Institutions27.72%
Short Interest
Short Ratio3.4d
Short % Float14.95%
Short % Out.14.57%
Shares Short1.87M
Short (prev mo.)1.83M
Technical
SMA 500.8856 (-54.8%)
SMA 2006.668 (-94.0%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)802.87K
Avg Vol (10d)1.69M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—